SUMMARY
The general control and surveillance of therapeutic drugs in Australia is discussed. Problems concerned with the systemic contraceptives, in particular the assessment of carcinogenicity arc detailed. It is suggested that monitoring and surveillance systems need to be extended and that the participation of Government in the field of hospital records, coding, morbidity statistics and research into drugrelated problems should be increased. Close international co‐operation in this area is suggested. The systemic contraceptives must be seen in correct perspective in the vast and expanding field of therapeutics. A plea is made for all parties concerned to develop a greater awareness of the many associated problems.